Copyright Reports & Markets. All rights reserved.

Global Hemophilia A Drug Sales Market Report 2019

Request for Sample of this report
Buy now

1 Study Coverage

  • 1.1 Hemophilia A Drug Product Introduction
  • 1.2 Market Segments
  • 1.3 Key Hemophilia A Drug Manufacturers Covered: Ranking by Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Hemophilia A Drug Market Size Growth Rate by Type
    • 1.4.2 ATXF-8117
    • 1.4.3 BAY-1093884
    • 1.4.4 BIVV-001
    • 1.4.5 BS-027125
    • 1.4.6 Concizumab
    • 1.4.7 CSL-689
    • 1.4.8 Others
  • 1.5 Market by Application
    • 1.5.1 Global Hemophilia A Drug Market Size Growth Rate by Application
    • 1.5.2 Clinic
    • 1.5.3 Hospital
    • 1.5.4 ASCs
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Executive Summary

  • 2.1 Global Hemophilia A Drug Market Size, Estimates and Forecasts
    • 2.1.1 Global Hemophilia A Drug Revenue 2015-2026
    • 2.1.2 Global Hemophilia A Drug Sales 2015-2026
  • 2.2 Global Hemophilia A Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
    • 2.2.1 Global Hemophilia A Drug Retrospective Market Scenario in Sales by Region: 2015-2020
    • 2.2.2 Global Hemophilia A Drug Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Hemophilia A Drug Competitor Landscape by Players

  • 3.1 Hemophilia A Drug Sales by Manufacturers
    • 3.1.1 Hemophilia A Drug Sales by Manufacturers (2015-2020)
    • 3.1.2 Hemophilia A Drug Sales Market Share by Manufacturers (2015-2020)
  • 3.2 Hemophilia A Drug Revenue by Manufacturers
    • 3.2.1 Hemophilia A Drug Revenue by Manufacturers (2015-2020)
    • 3.2.2 Hemophilia A Drug Revenue Share by Manufacturers (2015-2020)
    • 3.2.3 Global Hemophilia A Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
    • 3.2.4 Global Top 10 and Top 5 Companies by Hemophilia A Drug Revenue in 2019
    • 3.2.5 Global Hemophilia A Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Hemophilia A Drug Price by Manufacturers
  • 3.4 Hemophilia A Drug Manufacturing Base Distribution, Product Types
    • 3.4.1 Hemophilia A Drug Manufacturers Manufacturing Base Distribution, Headquarters
    • 3.4.2 Manufacturers Hemophilia A Drug Product Type
    • 3.4.3 Date of International Manufacturers Enter into Hemophilia A Drug Market
  • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

  • 4.1 Global Hemophilia A Drug Market Size by Type (2015-2020)
    • 4.1.1 Global Hemophilia A Drug Sales by Type (2015-2020)
    • 4.1.2 Global Hemophilia A Drug Revenue by Type (2015-2020)
    • 4.1.3 Hemophilia A Drug Average Selling Price (ASP) by Type (2015-2026)
  • 4.2 Global Hemophilia A Drug Market Size Forecast by Type (2021-2026)
    • 4.2.1 Global Hemophilia A Drug Sales Forecast by Type (2021-2026)
    • 4.2.2 Global Hemophilia A Drug Revenue Forecast by Type (2021-2026)
    • 4.2.3 Hemophilia A Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
  • 4.3 Global Hemophilia A Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)

  • 5.1 Global Hemophilia A Drug Market Size by Application (2015-2020)
    • 5.1.1 Global Hemophilia A Drug Sales by Application (2015-2020)
    • 5.1.2 Global Hemophilia A Drug Revenue by Application (2015-2020)
    • 5.1.3 Hemophilia A Drug Price by Application (2015-2020)
  • 5.2 Hemophilia A Drug Market Size Forecast by Application (2021-2026)
    • 5.2.1 Global Hemophilia A Drug Sales Forecast by Application (2021-2026)
    • 5.2.2 Global Hemophilia A Drug Revenue Forecast by Application (2021-2026)
    • 5.2.3 Global Hemophilia A Drug Price Forecast by Application (2021-2026)

6 North America

  • 6.1 North America Hemophilia A Drug by Country
    • 6.1.1 North America Hemophilia A Drug Sales by Country
    • 6.1.2 North America Hemophilia A Drug Revenue by Country
    • 6.1.3 U.S.
    • 6.1.4 Canada
  • 6.2 North America Hemophilia A Drug Market Facts & Figures by Type
  • 6.3 North America Hemophilia A Drug Market Facts & Figures by Application

7 Europe

  • 7.1 Europe Hemophilia A Drug by Country
    • 7.1.1 Europe Hemophilia A Drug Sales by Country
    • 7.1.2 Europe Hemophilia A Drug Revenue by Country
    • 7.1.3 Germany
    • 7.1.4 France
    • 7.1.5 U.K.
    • 7.1.6 Italy
    • 7.1.7 Russia
  • 7.2 Europe Hemophilia A Drug Market Facts & Figures by Type
  • 7.3 Europe Hemophilia A Drug Market Facts & Figures by Application

8 Asia Pacific

  • 8.1 Asia Pacific Hemophilia A Drug by Region
    • 8.1.1 Asia Pacific Hemophilia A Drug Sales by Region
    • 8.1.2 Asia Pacific Hemophilia A Drug Revenue by Region
    • 8.1.3 China
    • 8.1.4 Japan
    • 8.1.5 South Korea
    • 8.1.6 India
    • 8.1.7 Australia
    • 8.1.8 Taiwan
    • 8.1.9 Indonesia
    • 8.1.10 Thailand
    • 8.1.11 Malaysia
    • 8.1.12 Philippines
    • 8.1.13 Vietnam
  • 8.2 Asia Pacific Hemophilia A Drug Market Facts & Figures by Type
  • 8.3 Asia Pacific Hemophilia A Drug Market Facts & Figures by Application

9 Latin America

  • 9.1 Latin America Hemophilia A Drug by Country
    • 9.1.1 Latin America Hemophilia A Drug Sales by Country
    • 9.1.2 Latin America Hemophilia A Drug Revenue by Country
    • 9.1.3 Mexico
    • 9.1.4 Brazil
    • 9.1.5 Argentina
  • 9.2 Central & South America Hemophilia A Drug Market Facts & Figures by Type
  • 9.3 Central & South America Hemophilia A Drug Market Facts & Figures by Application

10 Middle East and Africa

  • 10.1 Middle East and Africa Hemophilia A Drug by Country
    • 10.1.1 Middle East and Africa Hemophilia A Drug Sales by Country
    • 10.1.2 Middle East and Africa Hemophilia A Drug Revenue by Country
    • 10.1.3 Turkey
    • 10.1.4 Saudi Arabia
    • 10.1.5 U.A.E
  • 10.2 Middle East and Africa Hemophilia A Drug Market Facts & Figures by Type
  • 10.3 Middle East and Africa Hemophilia A Drug Market Facts & Figures by Application

11 Company Profiles

  • 11.1 Bayer AG
    • 11.1.1 Bayer AG Corporation Information
    • 11.1.2 Bayer AG Description and Business Overview
    • 11.1.3 Bayer AG Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 Bayer AG Hemophilia A Drug Products Offered
    • 11.1.5 Bayer AG Related Developments
  • 11.2 BioMarin Pharmaceutical Inc
    • 11.2.1 BioMarin Pharmaceutical Inc Corporation Information
    • 11.2.2 BioMarin Pharmaceutical Inc Description and Business Overview
    • 11.2.3 BioMarin Pharmaceutical Inc Sales, Revenue and Gross Margin (2015-2020)
    • 11.2.4 BioMarin Pharmaceutical Inc Hemophilia A Drug Products Offered
    • 11.2.5 BioMarin Pharmaceutical Inc Related Developments
  • 11.3 Bioverativ Inc
    • 11.3.1 Bioverativ Inc Corporation Information
    • 11.3.2 Bioverativ Inc Description and Business Overview
    • 11.3.3 Bioverativ Inc Sales, Revenue and Gross Margin (2015-2020)
    • 11.3.4 Bioverativ Inc Hemophilia A Drug Products Offered
    • 11.3.5 Bioverativ Inc Related Developments
  • 11.4 Catalyst Biosciences Inc
    • 11.4.1 Catalyst Biosciences Inc Corporation Information
    • 11.4.2 Catalyst Biosciences Inc Description and Business Overview
    • 11.4.3 Catalyst Biosciences Inc Sales, Revenue and Gross Margin (2015-2020)
    • 11.4.4 Catalyst Biosciences Inc Hemophilia A Drug Products Offered
    • 11.4.5 Catalyst Biosciences Inc Related Developments
  • 11.5 Chugai Pharmaceutical Co Ltd
    • 11.5.1 Chugai Pharmaceutical Co Ltd Corporation Information
    • 11.5.2 Chugai Pharmaceutical Co Ltd Description and Business Overview
    • 11.5.3 Chugai Pharmaceutical Co Ltd Sales, Revenue and Gross Margin (2015-2020)
    • 11.5.4 Chugai Pharmaceutical Co Ltd Hemophilia A Drug Products Offered
    • 11.5.5 Chugai Pharmaceutical Co Ltd Related Developments
  • 11.6 CSL Ltd
    • 11.6.1 CSL Ltd Corporation Information
    • 11.6.2 CSL Ltd Description and Business Overview
    • 11.6.3 CSL Ltd Sales, Revenue and Gross Margin (2015-2020)
    • 11.6.4 CSL Ltd Hemophilia A Drug Products Offered
    • 11.6.5 CSL Ltd Related Developments
  • 11.7 DBV Technologies SA
    • 11.7.1 DBV Technologies SA Corporation Information
    • 11.7.2 DBV Technologies SA Description and Business Overview
    • 11.7.3 DBV Technologies SA Sales, Revenue and Gross Margin (2015-2020)
    • 11.7.4 DBV Technologies SA Hemophilia A Drug Products Offered
    • 11.7.5 DBV Technologies SA Related Developments
  • 11.8 Dimension Therapeutics Inc
    • 11.8.1 Dimension Therapeutics Inc Corporation Information
    • 11.8.2 Dimension Therapeutics Inc Description and Business Overview
    • 11.8.3 Dimension Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
    • 11.8.4 Dimension Therapeutics Inc Hemophilia A Drug Products Offered
    • 11.8.5 Dimension Therapeutics Inc Related Developments
  • 11.9 EpiVax Inc
    • 11.9.1 EpiVax Inc Corporation Information
    • 11.9.2 EpiVax Inc Description and Business Overview
    • 11.9.3 EpiVax Inc Sales, Revenue and Gross Margin (2015-2020)
    • 11.9.4 EpiVax Inc Hemophilia A Drug Products Offered
    • 11.9.5 EpiVax Inc Related Developments
  • 11.10 Expression Therapeutics LLC
    • 11.10.1 Expression Therapeutics LLC Corporation Information
    • 11.10.2 Expression Therapeutics LLC Description and Business Overview
    • 11.10.3 Expression Therapeutics LLC Sales, Revenue and Gross Margin (2015-2020)
    • 11.10.4 Expression Therapeutics LLC Hemophilia A Drug Products Offered
    • 11.10.5 Expression Therapeutics LLC Related Developments
  • 11.1 Bayer AG
    • 11.1.1 Bayer AG Corporation Information
    • 11.1.2 Bayer AG Description and Business Overview
    • 11.1.3 Bayer AG Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 Bayer AG Hemophilia A Drug Products Offered
    • 11.1.5 Bayer AG Related Developments
  • 11.12 Idogen AB
    • 11.12.1 Idogen AB Corporation Information
    • 11.12.2 Idogen AB Description and Business Overview
    • 11.12.3 Idogen AB Sales, Revenue and Gross Margin (2015-2020)
    • 11.12.4 Idogen AB Products Offered
    • 11.12.5 Idogen AB Related Developments
  • 11.13 Immusoft Corp
    • 11.13.1 Immusoft Corp Corporation Information
    • 11.13.2 Immusoft Corp Description and Business Overview
    • 11.13.3 Immusoft Corp Sales, Revenue and Gross Margin (2015-2020)
    • 11.13.4 Immusoft Corp Products Offered
    • 11.13.5 Immusoft Corp Related Developments
  • 11.14 LFB SA
    • 11.14.1 LFB SA Corporation Information
    • 11.14.2 LFB SA Description and Business Overview
    • 11.14.3 LFB SA Sales, Revenue and Gross Margin (2015-2020)
    • 11.14.4 LFB SA Products Offered
    • 11.14.5 LFB SA Related Developments
  • 11.15 mAbxience SA
    • 11.15.1 mAbxience SA Corporation Information
    • 11.15.2 mAbxience SA Description and Business Overview
    • 11.15.3 mAbxience SA Sales, Revenue and Gross Margin (2015-2020)
    • 11.15.4 mAbxience SA Products Offered
    • 11.15.5 mAbxience SA Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)

  • 12.1 Hemophilia A Drug Market Estimates and Projections by Region
    • 12.1.1 Global Hemophilia A Drug Sales Forecast by Regions 2021-2026
    • 12.1.2 Global Hemophilia A Drug Revenue Forecast by Regions 2021-2026
  • 12.2 North America Hemophilia A Drug Market Size Forecast (2021-2026)
    • 12.2.1 North America: Hemophilia A Drug Sales Forecast (2021-2026)
    • 12.2.2 North America: Hemophilia A Drug Revenue Forecast (2021-2026)
    • 12.2.3 North America: Hemophilia A Drug Market Size Forecast by Country (2021-2026)
  • 12.3 Europe Hemophilia A Drug Market Size Forecast (2021-2026)
    • 12.3.1 Europe: Hemophilia A Drug Sales Forecast (2021-2026)
    • 12.3.2 Europe: Hemophilia A Drug Revenue Forecast (2021-2026)
    • 12.3.3 Europe: Hemophilia A Drug Market Size Forecast by Country (2021-2026)
  • 12.4 Asia Pacific Hemophilia A Drug Market Size Forecast (2021-2026)
    • 12.4.1 Asia Pacific: Hemophilia A Drug Sales Forecast (2021-2026)
    • 12.4.2 Asia Pacific: Hemophilia A Drug Revenue Forecast (2021-2026)
    • 12.4.3 Asia Pacific: Hemophilia A Drug Market Size Forecast by Region (2021-2026)
  • 12.5 Latin America Hemophilia A Drug Market Size Forecast (2021-2026)
    • 12.5.1 Latin America: Hemophilia A Drug Sales Forecast (2021-2026)
    • 12.5.2 Latin America: Hemophilia A Drug Revenue Forecast (2021-2026)
    • 12.5.3 Latin America: Hemophilia A Drug Market Size Forecast by Country (2021-2026)
  • 12.6 Middle East and Africa Hemophilia A Drug Market Size Forecast (2021-2026)
    • 12.6.1 Middle East and Africa: Hemophilia A Drug Sales Forecast (2021-2026)
    • 12.6.2 Middle East and Africa: Hemophilia A Drug Revenue Forecast (2021-2026)
    • 12.6.3 Middle East and Africa: Hemophilia A Drug Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

  • 13.1 Market Opportunities and Drivers
  • 13.2 Market Challenges
  • 13.3 Market Risks/Restraints
  • 13.4 Porter's Five Forces Analysis
  • 13.5 Primary Interviews with Key Hemophilia A Drug Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis

  • 14.1 Value Chain Analysis
  • 14.2 Hemophilia A Drug Customers
  • 14.3 Sales Channels Analysis
    • 14.3.1 Sales Channels
    • 14.3.2 Distributors

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Research Methodology
      • 16.1.1 Methodology/Research Approach
      • 16.1.2 Data Source
    • 16.2 Author Details

    Hemophilia A Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Hemophilia A Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

    Segment by Type, the Hemophilia A Drug market is segmented into
    ATXF-8117
    BAY-1093884
    BIVV-001
    BS-027125
    Concizumab
    CSL-689
    Others

    Segment by Application, the Hemophilia A Drug market is segmented into
    Clinic
    Hospital
    ASCs

    Regional and Country-level Analysis
    The Hemophilia A Drug market is analysed and market size information is provided by regions (countries).
    The key regions covered in the Hemophilia A Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
    The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
    Competitive Landscape and Hemophilia A Drug Market Share Analysis
    Hemophilia A Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Hemophilia A Drug business, the date to enter into the Hemophilia A Drug market, Hemophilia A Drug product introduction, recent developments, etc.

    The major vendors covered:
    Bayer AG
    BioMarin Pharmaceutical Inc
    Bioverativ Inc
    Catalyst Biosciences Inc
    Chugai Pharmaceutical Co Ltd
    CSL Ltd
    DBV Technologies SA
    Dimension Therapeutics Inc
    EpiVax Inc
    Expression Therapeutics LLC
    Green Cross Corp
    Idogen AB
    Immusoft Corp
    LFB SA
    mAbxience SA

    Buy now